• Updated: March 3, 2021 1:58 p.m.
arrow Bottles of the Pfizer-BioNTech COVID-19 vaccine are prepared before the opening of a mass vaccination site in Queens. Seth Wenig/AP/Shutterstock
Last month, when a man collapsed and died after getting vaccinated for COVID-19 at the Javits Center shortly after the 15-minute observation period in which recipients are monitored for adverse reactions many news outlets reported that health officials did not believe it was related to the vaccine.
But they left the possibility open, just a crack. The incident might have served as one more seed of doubt for those still skeptical of the vaccines, which were developed and rolled out at a record pace.
Updated on March 3, 2021 at 8:33 pm
NBC Universal, Inc.
A major retailer apologized to a pregnant Alexandria woman after a Virginia pharmacy erroneously denied her the COVID-19 vaccine this week.
The apology comes after News4 reported Tiffany Del Rio was able to book a vaccination appointment at a Kroger pharmacy in Salem, near Roanoke, only for the pharmacy to cancel it days ahead of rolling up her sleeve. Download our NBC Washington app for iOS or Android to get alerts for local breaking news and weather.
According to Del Rio, a pharmacy employee told her they were canceling it because the Pfizer vaccine is “not recommended” for pregnant women, though state health officials and medical experts have said the coronavirus vaccines should not be withheld from pregnant women. What’s more, the Virginia Department of Health has included pregnancy among the underlying medical conditions that qualify someone to receive the vaccine.
Share this article
Share this article
MINNEAPOLIS and AUSTIN, Texas, March 3, 2021 /PRNewswire/ Bio-Techne Corporation (NASDAQ: TECH), a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities, today announced it has reached an agreement to acquire Asuragen, Inc. for initial consideration of $215 million in cash plus contingent consideration of up to $105 million upon the achievement of certain future milestones. The transaction will be financed through a combination of cash on hand and an existing revolving line of credit. Bio-Techne anticipates the acquisition to close in the fourth quarter of its fiscal 2021.
Founded in 2006, Asuragen is headquartered in Austin, Texas and is a leader in the development, manufacturing and commercialization of genetic carrier screening and oncology testing kits. Asuragen s products leverage proprietary chemistries which can be used on widely available platforms
ACOG Advises on Care for Transgender Patients medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.